uniQure (QURE) Other Non-Current Liabilities (2015 - 2026)
uniQure (QURE) recorded quarterly Other Non-Current Liabilities of $2.7 million in Q1 2026, down 26.76% quarter-over-quarter from $3.7 million in Q4 2025, and down 78.75% on a YoY basis from $12.6 million in Q1 2025.
uniQure (QURE) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
uniQure's Other Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 78.75% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $2.7 million (down 78.75% YoY), while the FY2025 annual figure was $3.7 million, down 66.34% from the prior year.
- Other Non-Current Liabilities was $2.7 million for Q1 2026 at uniQure, down from $3.7 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $36.9 million in Q1 2023 to a low of $960000.0 in Q2 2023.
- Historically, Other Non-Current Liabilities has averaged $11.9 million across 5 years, with a median of $9.3 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities slumped 96.7% in 2023, then surged 1158.12% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $9.3 million in 2022, then slumped by 60.36% to $3.7 million in 2023, then surged by 193.51% to $10.9 million in 2024, then tumbled by 66.34% to $3.7 million in 2025, then declined by 26.76% to $2.7 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $2.7 million (Q1 2026), $3.7 million (Q4 2025), and $17.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | uniQure | 2.88 Bn | 2.88 Bn | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.68 Mn |
| Dec 31, 2025 | 3.66 Mn |
| Sep 30, 2025 | 17.75 Mn |
| Jun 30, 2025 | 6.02 Mn |
| Mar 31, 2025 | 12.60 Mn |
| Dec 31, 2024 | 10.86 Mn |
| Sep 30, 2024 | 8.92 Mn |
| Jun 30, 2024 | 12.08 Mn |
| Mar 31, 2024 | 3.32 Mn |
| Dec 31, 2023 | 3.70 Mn |
| Sep 30, 2023 | 14.03 Mn |
| Jun 30, 2023 | 960,000.00 |
| Mar 31, 2023 | 36.90 Mn |
| Dec 31, 2022 | 9.33 Mn |
| Sep 30, 2022 | 9.16 Mn |
| Jun 30, 2022 | 29.10 Mn |
| Mar 31, 2022 | 22.06 Mn |
| Dec 31, 2021 | 4.24 Mn |
| Sep 30, 2021 | 3.81 Mn |
| Jun 30, 2021 | 3.25 Mn |